H.C. Wainwright analyst Matthew Caufield adjusted the firm’s price target on Immunic (IMUX) to $22 from $5 and keeps a Buy rating on the shares. The firm cites the company’s 1-for-10 reverse stock split for the target change.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/29/26?
- Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/28/26?
- Immunic Appoints Veteran Neurology Leader as Chief Medical Officer
- Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed
- Upcoming Stock Splits This Week (April 27 to May 1) – Stay Invested